Hepatitis A and E in South America: New Challenges Toward Prevention and Control

Pinto, Marcelo Alves; Oliveira, Jaqueline Mendes de; González, Jorge

doi:10.1007/978-3-319-54567-7_7

Cited by 2 publications

(3 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Years later, in 1983, HEV was first identified by electron microscopy when they replicated the infection with a pool of human feces in one volunteer who had previously contacted with hepatitis A virus. It was also the first time to detect genotype 1 [ 4 , 5 ].…”

Section: History Of Hepatitis Ementioning

confidence: 99%

“…In 1988, an outbreak in Somalia, Africa, was reported reaching 11,000 people [ 7 ]. In Latin America, the first detection of HEV was described in Mexico, during an outbreak between 1986 and 1987, with detection of genotype 2 [ 5 , 8 ]. The largest epidemic described was in China between 1986 and 1988, presenting 120,000 people with the disease caused by genotype 1 [ 9 ].…”

Section: History Of Hepatitis Ementioning

confidence: 99%

“…In the Americas, the seroprevalence of anti-HEV IgG ranges from 3 to 31%, which can be explained by the sporadic HEV cases reported in the area [ 29 , 64 , 65 ]. Genotypes 1 through 3 have been documented in humans and animals in Uruguay (HEV-1 and HEV-3), Colombia (HEV-3), Argentina (HEV-3), Mexico (HEV-2, only humans), Venezuela (HEV-1 and HEV-3), Brazil (HEV-3), and the United States of America (HEV-3) [ 5 , 8 , 10 , 29 , 64 – 70 ].…”

Section: Epidemiologymentioning

confidence: 99%

See 2 more Smart Citations

Hepatitis E: Update on Prevention and Control

Melgaço

Gardinali

Mello

et al. 2018

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Hepatitis E virus (HEV) is a common etiology of acute viral hepatitis worldwide. Recombinant HEV vaccines have been developed, but only one is commercially available and licensed in China since 2011. Epidemiological studies have identified genotype 3 as the major cause of chronic infection in immunocompromised individuals. Ribavirin has been shown to be effective as a monotherapy to induce HEV clearance in chronic patients who have undergone solid organ transplant (SOT) under immunosuppressive therapy. Efforts and improvements in prevention and control have been made to reduce the instances of acute and chronic hepatitis E in endemic and nonendemic countries. However, this review shows that further studies are required to demonstrate the importance of preventive vaccination and treatment worldwide, with emphasis on hepatitis E infection in the public health system.

show abstract

Section: History Of Hepatitis Ementioning

confidence: 99%